For patients with coronary artery disease (CAD), cardiac interventional procedures are a critical method to open blocked vessels and save heart muscle. The precision of the procedure directly determines treatment outcomes and long-term prognosis. On March 25, 2026, Philips’ IntraSight Plus multimodal “one-stop” cardiac interventional fusion platform received FDA approval in the U.S. and CE certification in the EU. This breakthrough completely overcomes the limitations of traditional interventional procedures, bringing qualitative improvements in precision, safety, and efficiency, and introducing a new era in global coronary artery disease treatment.

1. From “Multiple Screens” to “Three-in-One”: Core Technological Breakthrough

In traditional cardiac interventions, physicians must simultaneously reference three types of imaging: DSA (Digital Subtraction Angiography), IVUS (Intravascular Ultrasound), and FFR (Fractional Flow Reserve). These data are dispersed across different devices and interfaces. Constantly switching between them is time-consuming and may affect decision-making, particularly in complex lesion treatments.

As an upgrade of the 2019 first-generation platform, IntraSight Plus achieves a leap from “dual-fusion” to “triple-fusion.” For the first time, DSA, IVUS, and FFR are integrated into a single operating interface, realizing “three-in-one” visualization.

After selecting the target vessel, physicians can view vessel morphology, plaque structure, myocardial ischemia, and stent planning simultaneously on the same screen. This eliminates the need to switch between multiple systems and significantly improves procedural fluency and decision-making efficiency.

2026版 vs. 2019版

2. Three Core Technologies: The Synergistic Value of “Triple Fusion”

The advantages of IntraSight Plus come from the deep integration of three technologies, which complement each other to overcome the limitations of single modalities, achieving a “1+1+1>3” diagnostic and therapeutic effect.

• DSA: The “Navigation Map” of Surgery
  DSA is the foundation of cardiac intervention, providing a clear view of coronary vessel course, stenosis location, and degree, supporting procedural positioning. However, it only shows the lumen contour and cannot penetrate the vessel wall to assess plaque structure or myocardial ischemia.
• IVUS: The “High-Definition Microscope” Inside the Vessel
  IVUS uses an intravascular ultrasound probe to clearly visualize plaque morphology and vessel wall thickness, accurately assessing stenosis severity and evaluating stent apposition. However, it lacks macroscopic navigation, making precise probe positioning difficult.
• FFR: The “Functional Gold Standard” for Myocardial Ischemia
  FFR measures pressure ratios to determine the impact of stenosis on myocardial blood supply, preventing unnecessary stenting. However, it only provides functional data and cannot directly guide stent placement or sizing.

By integrating these three technologies, physicians can simultaneously understand the vessel’s macroscopic structure, plaque microstructure, and myocardial ischemia function, achieving comprehensive “anatomical + functional” assessment for more scientific decision-making.

3. Dual Benefits: For Patients and Clinicians

• For Patients: Safer, More Precise, and Reassuring

Patients directly benefit from the platform:

FFR accurately identifies ischemia, avoiding overtreatment and unnecessary trauma.

The one-stop interface shortens procedure time, reduces radiation exposure, and lowers contrast agent use, decreasing complication risk.

Accurate stent planning and apposition assessment reduce long-term complications and support postoperative recovery.

• For Clinicians: More Efficient, Precise, and Stress-Free

For clinicians, the platform is a powerful tool to enhance diagnostic and treatment capabilities:

Improves procedural efficiency and reduces workload, suitable for complex coronary lesions.

Multimodal information aids in precise lesion identification and optimal strategy development, improving procedural success rates.

Intuitive interface lowers the learning curve, promoting wider adoption of interventional techniques.

4. Industry Significance: Ushering in a “Precision” Era in Cardiac Intervention

The launch of IntraSight Plus marks a milestone in cardiac interventional imaging, signaling the industry’s move from “single modality” and “dual-fusion” toward a new era of “triple multimodal fusion.” It lays the foundation for precision and intelligent intervention, promoting coronary interventions guided by combined “functional and imaging” assessment, in line with global precision medicine trends.

The platform also leaves room for future technological expansion, potentially integrating OCT and AI-assisted diagnostics, and extending applications to peripheral vascular and structural heart diseases, continuously driving industry innovation.

5. The “Behind-the-Scenes Hero” in Device Development: Dewell Medical Supports Precise Interventions

The clinical application of cutting-edge interventional platforms depends on device development and testing support. Xi’an Dewell Medical, an innovative company focused on intelligent medical simulation technology, provides critical testing and validation services for interventional devices, ensuring safe clinical deployment of high-end devices.

Dewell Medical’s core team comes from renowned domestic and international universities and research institutes, specializing in 3D printing, hemodynamics, and medical simulation. They master 3D modeling and biomimetic manufacturing, providing micro-invasive intervention simulation testing solutions for medical device engineers.

Dewell Medical Simulation Model — One-Step Fabrication of Complex Vessels, Accurately Replicating Human Vascular Anatomy and Functional Characteristics

For cardiac interventional device testing, Dewell Medical creates highly realistic simulation models and test systems:

1:1 replication of coronary anatomy based on real human data, compatible with IntraSight Plus multimodal imaging assessment.

High-transparency soft silicone material reproduces vascular physiological properties.

Equipped with professional testing devices to accurately assess device performance, supporting design optimization and preclinical validation.

As IntraSight Plus clinical application demands higher device precision and compatibility, Dewell Medical’s simulation solutions provide a “virtual clinical” testing environment, helping engineers optimize products and ensure perfect synergy with the platform for safer and more precise patient treatment.

Dewell Medical Product Showcase

6. Conclusion

The launch of IntraSight Plus provides coronary artery disease patients with safer and more precise treatment options, and gives clinicians an efficient diagnostic tool, advancing cardiac intervention toward precision and intelligence.

Medical simulation companies, represented by Dewell Medical, use cutting-edge simulation technology to strengthen device development and testing, supporting the clinical implementation of innovative technologies. With FDA and CE certification already obtained, the platform is expected to accelerate its entry into the Chinese market, promoting a comprehensive upgrade of domestic cardiac interventional capabilities.